



Argos Therapeutics  
Investor Relations Department  
4233 Technology Drive  
Durham, NC 27704  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: ARGS**


Last Trade:	1.37
Trade Time:	4:00 PM ET Feb 20, 2018
Change:	-0.08  (-5.517%)
Day Range	1.33 - 1.47
52-Week Range	1.39 - 96.00
Volume	274,566

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Feb 15, 2018*

[Argos Announces Issuance of Patent Covering the Foundation<sup>®</sup> for Manufacturing its HIV Immunotherapy](#)

*Feb 5, 2018*

[Argos Obtains Option to License PD1 Checkpoint Inhibitors](#)

*Jan 18, 2018*

[Argos Announces One-for-Twenty Reverse Stock Split](#)

*Jan 8, 2018*

[Argos Announces \\$1.5 Million Equity Investment by Lummy \(Hong Kong\), Ltd.](#)

*Nov 28, 2017*

[Argos Provides Financial Update](#)

## Financials [\[ View all \]](#)

*Mar 16, 2017*

[Annual Report \(10-K\)](#)

*Jul 6, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Nov 9, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 9, 2017*

[Quarterly Report \(10-Q\)](#)

*May 10, 2017*

[Quarterly Report \(10-Q\)](#)